Department of Public Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
Pediatr Res. 2018 Sep;84(3):328-332. doi: 10.1038/s41390-018-0035-7. Epub 2018 Jul 6.
The amount of federal dollars allocated to improving the health of our pediatric population can serve as an indicator of the priority placed on child well-being. Although Congress has established novel mechanisms that marginally increase pediatric research funding, the pediatric research portfolio is facing an increasingly uncertain fate.
This work examines pediatric, perinatal and pediatric research initiative (PRI) spending using data collected by the NIH that uses the novel research, condition and disease categorization system. Further, this work reports on recent policy developments in pediatric biomedical research and offers recommendations to insulate this portfolio from future uncertainty.
Federal support for pediatric research has declined with average annual growth rates of NIH pediatric spending dropping from 12.8% (FY 1998-2003) to 1.7% (FY 2004-2015). After taking into account Biomedical Research and Development Price Index growth, the pediatric research portfolio's purchasing power has declined by 15.9% (FY 2004-2015).
Federal support for pediatric biomedical research has plateaued in nominal terms and declined significantly in real terms. Future congressional action will be necessary to protect gains and to expand the capacity of the pediatric portfolio.
用于改善儿科人群健康的联邦资金数额可以作为儿童福祉优先程度的一个指标。尽管国会已经建立了一些新的机制,使儿科研究资金略有增加,但儿科研究组合仍面临着越来越不确定的命运。
本研究使用 NIH 收集的数据,通过新颖的研究、疾病分类系统,对儿科、围产期和儿科研究倡议(PRI)支出进行了考察。此外,本研究还报告了儿科生物医学研究的最新政策发展,并提出了建议,以保护这一投资组合免受未来的不确定性影响。
联邦政府对儿科研究的支持有所减少,NIH 儿科支出的年均增长率从 1998-2003 财年的 12.8%降至 2004-2015 财年的 1.7%。考虑到生物医学研究与开发价格指数的增长,儿科研究组合的购买力在 2004-2015 财年下降了 15.9%。
联邦政府对儿科生物医学研究的支持在名义上趋于稳定,而实际支持则大幅下降。未来国会需要采取行动,以保护既得利益并扩大儿科投资组合的规模。